Featured
Lead report
美股
Lead report
Ingredion Guides 2026 EPS to $10.30-$10.90, Targets $130M Synergies from Tate & Lyle Deal
Ingredion projects 2026 adjusted EPS of $10.30-$10.90 and confirms $130 million annual run-rate synergies from its Tate & Lyle acquisition by 2030, signaling confidence in its specialty ingredients strategy amid industry consolidation.
美股
Ingredion Q2 2026 Earnings Preview: Cost Pressures and Specialty Ingredients Growth in Focus
Ingredion is set to report Q2 2026 earnings, with investors eyeing specialty ingredients growth, cost management, and full-year guidance amid raw material volatility and mixed global demand.
美股
This Week's Blockbuster Deals: GSK, Incyte, Ingredion, OpenAI Lead US Stock Market Trends
A deep dive into key US stock market moves this week, including GSK's consumer health divestiture, Incyte's acquisition of MorphoSys, Ingredion's South American business sale, and OpenAI's $40 billion funding round, along with updates on Tesla, Apple, and Amazon.
